#USA #Creatv Bio #Monmouth Junction #LifeTracDx #mTNBC

Revolutionary Blood Test for Metastatic Triple-Negative Breast Cancer

Creatv Bio, part of Creatv MicroTech, Inc., has recently unveiled groundbreaking findings that could change the landscape of treatment for metastatic triple-negative breast cancer (mTNBC). In collaboration with CytoDyn Inc., the company conducted a four-year survival analysis that revealed significant correlations between PD-L1 upregulation monitored through their innovative LifeTracDx blood test and treatment outcomes in cancer patients. This development is particularly exciting for those grappling with mTNBC, a particularly aggressive form of breast cancer.

The analysis focused on a cohort of 28 patients diagnosed with mTNBC who were treated with leronlimab, a promising CCR5 antagonist, both independently and in combination with PD-L1 immune checkpoint inhibitors (ICIs). The results, which were shared at the ESMO Breast Cancer meeting held on May 15, 2025, indicated that patients receiving leronlimab exhibited a significant increase in PD-L1 expression on circulating tumor-associated cells. The LifeTracDx test was pivotal in monitoring these changes, validating its effectiveness as a real-time tracking tool for cancer response.

Purpose of LifeTracDx Blood Test

The LifeTracDx blood test stands out due to its dual analysis of circulating tumor cells (CTCs) alongside Cancer Associated Macrophage-Like (CAML) cells. This innovative approach allows it to accurately detect tumor responses and guide treatment regimens effectively. In the trials presented at ESMO, an impressive 76% of patients experienced upregulated PD-L1 expression after initiating therapy with leronlimab, as measured by the LifeTracDx test. Furthermore, a notable follow-up study revealed that five patients exhibiting this upwards trend in PD-L1 and subsequently treated with ICIs such as atezolizumab or pembrolizumab remained alive four years post-treatment.

Significance of PD-L1 Monitoring

Monitoring PD-L1 levels is vital for understanding the tumor microenvironment and predicting treatment outcomes. In breast cancer, particularly the triple-negative subtype, assessing PD-L1 expression can influence therapy decisions. By utilizing the LifeTracDx blood test, oncologists can make informed choices regarding the use of ICIs, which are designed to unleash the immune system against tumors by blocking key inhibitory pathways.

The implications of these findings could extend beyond mTNBC, potentially impacting various cancer types and treatment strategies. Creatv Bio is committed to further research and development in this field, attempting to ensure that their blood test maximizes its diagnostic and prognostic capabilities.

About Creatv Bio

Creatv Bio operates from its New Jersey laboratory, focusing on cancer screening and diagnostic services tailored to aid both patients and pharmaceutical companies. Since their inception, they have forged a path in cancer diagnostics, being the first to identify CAMLs in blood samples of cancer patients, and have established a reputation for innovative cancer monitoring techniques. The LifeTracDx test's diverse applications span from predicting therapeutic responses to aiding in the early detection of cancer recurrences, thus playing an integral role in comprehensive cancer care.

For further details on Creatv Bio's research and their contributions to oncology, interested parties are encouraged to explore their official resources and publications available online. The landscape of cancer treatment is rapidly evolving, and with advancements like the LifeTracDx test, there is renewed optimism for more effective therapies and improved patient outcomes in the fight against cancer.